New breast cancer drug challenges standard treatment in major trial
NCT ID NCT07492641
Summary
This study compares a new drug combination (BGB-43395 plus letrozole) against current standard treatments for advanced breast cancer that has spread. It will involve over 1,000 adults with hormone-positive, HER2-negative breast cancer who haven't received prior treatment for their advanced disease. The main goal is to see if the new combination helps patients live longer without their cancer getting worse compared to existing options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.